Changeflow GovPing Healthcare & Life Sciences Dragonfly Therapeutics NKG2D CD16 Tumor Antigen...
Routine Rule Added Final

Dragonfly Therapeutics NKG2D CD16 Tumor Antigens Patent

Favicon for changeflow.com EPO Patent Bulletin - Peptides (C07K)
Published
Detected
Email

Summary

The European Patent Office has published patent application EP3833385A1 filed by Dragonfly Therapeutics, Inc. on April 15, 2026, covering tri-specific proteins binding NKG2D, CD16, and a tumor-associated antigen. The application names eleven inventors including CHANG, Gregory, P., CHEUNG, Ann, F., and others, and classifies under IPC codes A61K 39/00 and C07K 16/28. Designated states include all EPO member states including Germany, France, the United Kingdom, Italy, Spain, and 27 other European jurisdictions.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors EPO Patent Bulletin - Peptides (C07K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 46 changes logged to date.

What changed

The EPO published Dragonfly Therapeutics' patent application EP3833385A1 for tri-specific proteins designed to simultaneously bind NKG2D, CD16, and a tumor-associated antigen. The publication makes the invention publicly available and establishes priority dates for the immunotherapy technology. IPC classifications indicate applications in medicinal preparations containing antigens or antibodies (A61K 39/00) and immunoglobulins (C07K 16/28).

Competitors developing bispecific or tri-specific cancer immunotherapy candidates should monitor the EPO examination progress for this application, as a granted patent could affect freedom-to-operate in designated EPO member states. The publication itself does not create enforceable rights but puts the technology in the public domain for prior art purposes.

Archived snapshot

Apr 24, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

PROTEINS BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN

Publication EP3833385A1 Kind: A1 Apr 15, 2026

Applicants

Dragonfly Therapeutics, Inc.

Inventors

CHANG, Gregory, P., CHEUNG, Ann, F., DU, Jinyan, GRINBERG, Asya, HANEY, William, LUNDE, Bradley, M., PRINZ, Bianka, FALLON, Daniel, O'NEIL, Steven, WEI, Ronnie

IPC Classifications

A61K 39/00 20060101AFI20211115BHEP C07K 16/28 20060101ALI20211115BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 15th, 2026
Instrument
Rule
Branch
International
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP3833385A1

Who this affects

Applies to
Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent filing Intellectual property
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!